Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Leukemia & Lymphoma Society (LLS) and The Institute for Follicular Lymphoma Innovation (IFLI): Research Accelerator for Follicular Lymphoma (RAFL) Program

Research Admin Offices:

  • HRS

Funding Type:

Grant

Opportunity Type:

  • Grant

Value:

Synergistic Team Awards (STA) – $6.5 M total award; $1.3M/yr. for up to 5 years of funding.
Translational Awards (TRL) – Up to $1.75M total award; $350,000/yr. for up to 5 years of funding.

Disciplines:

  • Health Sciences

Sponsors:

  • Leukemia & Lymphoma Society

Deadlines:

Internal Deadline:

August 26, 2024

Sponsor Deadline:

September 9, 2024

Additional Dates:

  • LOI HRS Due Date - August 26, 2024
  • LOI Sponsor Due Date - September 9, 2024

Description:

LLS and The Institute for Follicular Lymphoma Innovation have teamed up for the Research Accelerator for Follicular Lymphoma (RAFL), to advance the development of new therapeutic options and monitoring strategies that will address key unmet need in Follicular Lymphoma. Potential areas of interest include:

  • New Therapeutic Development
  • Target identification
  • Follicular Lymphoma Biology
  • Biomarker Discovery and Development
  • Monitoring and Diagnostics
  • Translations Tools and Technologies

It supports Synergistic Team Awards (STA) and Translational Awards (TRL), encouraging international and US-based researchers to collaborate across disciplines and with industry partners. Projects should aim for high impact in discovery, translational, and clinical research, targeting critical challenges in FL with the ultimate goal of improving patient outcomes and discontinuing therapy.

Resources:

Additional Details.

Contact:

If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.